Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Blogs
    • AI
    • Deals
    • Layoff Tracker
    • HIMSS 2023
  • Opinion
    • Breaking Bias
    • Commentaries
    • Letters
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - AI and Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Sponsored Video Series - One on One
    • Sponsored Video Series - Checking In with Dan Peres
  • Data & Insights
    • Data & Insights Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Finance
July 25, 2015 12:00 AM

Pressure mounts for measures to control drug prices

Sabriya Rice
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Dr. Pearson

    The pharmaceutical industry is facing growing pushback on high prescription drug costs.

    Last week, more than 100 cancer specialists from across the country published a letter urging more aggressive federal steps to address soaring drug prices, which they said harm patients. They noted that cancer patients who receive life-prolonging drugs often face bills that are several times greater than their annual family income.

    They urged allowing the Patient-Centered Outcomes Research Institute to include drug pricing in its assessments of a treatment's value, and letting Medicare negotiate lower drug prices.

    In addition, the cancer specialists recommended creating a mechanism to review fair pricing for drugs approved by the Food and Drug Administration.

    Federal law prohibits the CMS from negotiating drug prices for Medicare, and generally bars HHS from considering cost in Medicare coverage decisions. Efforts several years ago to allow consideration of cost in comparative-effectiveness research prompted a conservative firestorm over alleged “death panels.”

    But a growing number of policymakers and healthcare industry groups are pressing for action to reduce drug prices, and public opinion polls show strong support.

    Also last week, the Institute for Clinical and Economic Review (ICER) announced it would begin releasing reports comparing clinical effectiveness and prices of drugs, as well as analyzing their potential impact on the U.S. healthcare system and economy.

    The not-for-profit organization will set a value-based benchmark for pricing. The project is funded by a new $5.2 million grant from the Laura and John Arnold Foundation.

    “What we're trying to do is create a transparent way to look at the relationship of the price with the value the drug brings to patients,” ICER President Dr. Steven Pearson said. “Drug prices have been trending upward quite dramatically in recent years. But the idea that insurers are just going to cover any new drug, at any price, whether or not there is benefit, is over.”

    MH Takeaways

    A growing number of policymakers and healthcare industry groups are pressing for action to reduce drug prices, and public opinion polls show strong support.

    In a third development last week, a white paper published by advocacy group Public Citizen and Carleton University found that the CMS could save up to $16 billion a year if it negotiated prices with drugmakers for the Part D program and wrangled the same prices paid by Medicaid or the Veterans Health Administration. The authors said U.S. costs per capita for drugs are $1,010, more than twice as much as in other advanced countries that belong to the Organization for Economic Cooperation and Development (OECD).

    “The good news is that effective new cancer therapies are being developed by pharmaceutical and biotechnology companies,” according to the letter signed by more than 100 cancer specialists and posted online in the Mayo Clinic Proceedings. But “the current pricing system is unsustainable and not affordable for many patients.”

    The cost of a newly approved therapy averages $10,000 a month, with some exceeding $30,000 a month, according to estimates. The number of Americans taking at least $100,000 worth of prescription drugs annually tripled from 2013 to 2014, a recent report found.

    The cancer specialists' letter suggested that the CMS be allowed to negotiate drug prices for Medicare as a whole. Although the agency cannot negotiate prices with pharmaceutical companies, private Part D drug plans, Medicare Advantage plans, state Medicaid programs and the VHA are allowed to negotiate.

    The Public Citizen's white paper reported that Part D plans pay on average 73% more than Medicaid and 80% more than the VHA for brand-name drugs. It also said Part D plans pay nearly twice the median amount paid for brand-name drugs in the 31 OECD nations, most of which have systems for negotiating drug prices.

    The pharmaceutical industry and many Republicans vehemently oppose allowing the CMS to negotiate drug prices.

    The first ICER evaluations will focus on PCSK9 inhibitors for cholesterol and a new Novartis heart failure drug called Entresto.

    Pearson said the U.S. needs an independent, objective source to look at the evidence on clinical effectiveness and then focus on the incremental costs downstream.

    Dr. Peter Bach, director of the Center for Health Policy and Outcomes at the Memorial Sloan Kettering Cancer Center in New York City, said he agreed that an independent body is needed to objectively evaluate the evidence on clinical effectiveness.

    In mid-June he launched a website called DrugAbacus as a roadmap for comparing particular drugs' potential harms with the quality-of-life years they provide, and to use this calculus to come up with appropriate pricing for the drug.

    “Right now, patients don't have any fair boundaries for absolutely vital health decisions,” he said. “It's totally unreasonable and unfair.”

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Copy of finance_arrows_down_WEB_i_i_i.jpg
    Dozens of hospitals, health systems see credit rating downgrades
    Copy of states hospital costs_WEB_i.jpg
    Mark Cuban-backed study finds price discrepancies in hospital services
    Most Popular
    1
    Centene to lay off 2,000 workers
    2
    How health systems are battling price-gouging allegations
    3
    Senate advances bill to temporarily aid hospitals, health centers
    4
    Elevance, Blue Cross Louisiana halt $2.5B proposed deal
    5
    Tower Health to sell urgent care centers, close others
    Sponsored Content
    Daily Finance Newsletter: Sign up to receive daily news and data that has a direct impact on the business and financing of healthcare.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Help Center
    • Advertise with Us
    • Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Blogs
      • AI
      • Deals
      • Layoff Tracker
      • HIMSS 2023
    • Opinion
      • Breaking Bias
      • Commentaries
      • Letters
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - AI and Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Sponsored Video Series - One on One
      • Sponsored Video Series - Checking In with Dan Peres
    • Data & Insights
      • Data & Insights Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing